Suchergebnisse - "McAuley, Daniel F"

PubPharm (412)

61

Inflammatory sub-phenotypes in sepsis: relationship to outcomes, treatment effect and transcriptomic sub-phenotypes

enthalten in: bioRxiv.org | 2022

von Antcliffe, D. | Mi, Y. | Santhakumaran, S. | +15

62

The Influence of Orthopedic Surgery on Circulating Metabolite Levels, and their Associations with the Incidence of Postoperative Delirium

enthalten in: Metabolites | 2022

von Jung, M. | Pan, X. | Cunningham, E. | +9

63

Redefining critical illness

enthalten in: Nature medicine | 2022

von Maslove, D. | Tang, B. | Shankar-Hari, M. | +36

64

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS : a secondary analysis of the HARP-2 randomised clinical trial

enthalten in: Critical care (London, England) | 2022

von Boyle, A. | Ferris, P. | Bradbury, I. | +5

65

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

enthalten in: Critical care | 2022

von Boyle, A. | Ferris, P. | Bradbury, I. | +5

66

Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients

enthalten in: EBioMedicine | 2022

von Page, V. | Watne, L. | Heslegrave, A. | +4

67

enthalten in: Chest | 2022

von Toner, P. | McAuley, D. | O'Kane, C.

CommentOn: Chest. 2022 May;161(5):1275-1284. - PMID 34785236

68

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

enthalten in: bioRxiv.org | 2022

von Heath, P. | Galiza, E. | Baxter, D. | +42

69

Noninvasive Respiratory Strategies and Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19-Reply

enthalten in: JAMA | 2022

von Couper, K. | Connolly, B. | McAuley, D.

CommentOn: JAMA. 2022 May 24;327(20):2023. - PMID 35608589

70

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) : a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial

enthalten in: Trials | 2022

von Gorman, E. | Shankar-Hari, M. | Hopkins, P. | +18